Galapagos to present promising findings in cystic fibrosis programs at NACFC 2015
(Thomson Reuters ONE) -
Five poster presentations cover progress and depth of discovery and development
efforts in CF
Mechelen, Belgium; 8 October 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) is
present with a strong delegation presenting or contributing to five posters at
the North American Cystic Fibrosis Conference (NACFC) in Phoenix this week.
Thursday, 8 October 11.50 AM - 1.50 PM MST
All posters
Friday, 9 October 7.30 AM - 8.45 AM
Poster 50
Potentiators: how do they impact the fate of CFTR during biogenesis?
Insights are presented on the contribution of GLPG1837 to the rescue of F508del
CFTR
Poster 70
Insight into the mechanisms of correctors and potentiators
Galapagos and Abbvie developed new tools to better understand the mechanism of
action of correctors and potentiators in its CF portfolio
Poster 62
Using BLISS analysis to categorize corrector-corrector interactions
Galapagos and AbbVie disclose the usage of a modelling tool to categorize
interactions between candidate corrector compounds in their CF program
Poster 258
Safety, tolerability and pharmacokinetics of a novel CFTR Potentiator GLPG1837
in healthy volunteers
Galapagos presents safety and tolerability of GLPG1837 in healthy human
volunteers, paving the path for the Phase 2 study in Class III mutation patients
to start by end 2015. More information on this poster will be published later
during the conference.
Saturday, 10 October 7.30 AM - 8.45 AM
Poster 219
Novel Potentiators Augment Efficacy of Translational Readthrough in CFTR
Nonsense Mutations
Promising pre-clinical data using Galapagos potentiators on Class I (nonsense)
CFTR mutations is presented
These posters will be made available on the Galapagos website, www.glpg.com,
shortly following the presentation sessions.
The North American Cystic Fibrosis Conference is sponsored by the Cystic
Fibrosis Foundation:
www.cff.org
About cystic fibrosis (CF)
CF is a rare, life-threatening, genetic disease that affects approximately
80,000 patients worldwide and approximately 30,000 patients in the United
States. CF is a chronic disease that affects the lungs and digestive system.
CF patients, with significantly impaired quality of life, have an average
lifespan approximately 50% shorter than the population average, with the median
age of death at 27. There currently is no cure for CF. CF patients require
lifelong treatment with multiple daily medications, frequent hospitalizations
and ultimately lung transplant, which is life-extending but not curative. CF is
caused by a mutation in the gene for the CFTR protein, which results in abnormal
transport of chloride across cell membranes. Transport of chloride is required
for effective hydration of epithelial surfaces in many organs of the body.
Normal CFTR channel moves chloride ions to outside of the cell. Mutant CFTR
channel does not move chloride ions, causing sticky mucous to build up on the
outside of the cell. CFTR dysfunction results in dehydration of dependent
epithelial surfaces, leading to damage of the affected tissues and subsequent
disease, such as lung disease, malabsorption in the intestinal tract and
pancreatic insufficiency.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other indications.
Filgotinib is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases. Galapagos
has reported good activity and a favorable safety profile in both the DARWIN 1
and 2 trials in RA. Galapagos is preparing to enter Phase 3 studies in RA and
to report Phase 2 topline results with filgotinib in Phase 2 in Crohn's disease.
In the field of cystic fibrosis, AbbVie and Galapagos signed a collaboration
agreement to develop and commercialize molecules that address mutations in the
CFTR gene. Potentiator GLPG1837 has completed a Phase 1 trial, and corrector
GLPG2222 is expected to enter Phase 1 by end 2015. GLPG1205, a first-in-class
inhibitor of GPR84 and fully-owned by Galapagos, will report topline results in
Q4 2015 from a Phase 2 proof-of-concept trial in ulcerative colitis patients.
GLPG1690, a fully proprietary, first-in-class inhibitor of autotaxin, has shown
favorable safety in a Phase 1 trial and is expected to enter Phase 2 in
idiopathic pulmonary fibrosis. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. More info at www.glpg.com
CONTACT
Galapagos NV
Investors:
Elizabeth Goodwin, VP IR & Corporate Communications
Cell: +1 781 460 1784
Media inquiries:
Evelyn Fox, Director Communications
Tel: +31 6 53 591 999
ir(at)glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including statements
regarding the promising findings demonstrated in the Company's product
candidates for cystic fibrosis. Galapagos cautions the reader that forward-
looking statements are not guarantees of future performance. Forward-looking
statements involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition and liquidity,
performance or achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions and
liquidity, performance or achievements expressed or implied by such forward-
looking statements. In addition, even if Galapagos' results, performance,
financial condition and liquidity, and the development of the industry in which
it operates are consistent with such forward-looking statements, they may not be
predictive of results or developments in future periods. Among the factors that
may result in differences are the inherent uncertainties associated with
competitive developments, clinical trial and product development activities and
regulatory approval requirements (including that data from Galapagos' ongoing
clinical research programs in cystic fibrosis may not support registration or
further development of potentiators and/or correctors due to safety, efficacy or
other reasons), Galapagos' reliance on collaborations with third parties
(including its collaboration partner, AbbVie, who may not devote sufficient
resources to the development and commercialization of the cystic fibrosis
programs), and estimating the commercial potential of our product candidates. A
further list and description of these risks, uncertainties and other risks can
be found in the company's Securities and Exchange Commission filing and reports,
including in the company's prospectus filed with the SEC on May 14, 2015 and
future filings and reports filed by the company with the Securities and Exchange
Commission. Given these uncertainties, the reader is advised not to place any
undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any such forward-looking statements
in this document to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any such statement
is based or that may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements, unless specifically required
by law or regulation.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1957556]
Unternehmensinformation / Kurzprofil:
Datum: 08.10.2015 - 07:31 Uhr
Sprache: Deutsch
News-ID 425579
Anzahl Zeichen: 9214
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 205 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos to present promising findings in cystic fibrosis programs at NACFC 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
